TY - JOUR
T1 - Overcoming barriers to advanced biomolecular technologies that inform treatment of solid tumors
T2 - a roadmap to access
AU - Garcia-Foncillas, Jesús
AU - Bayle, Arnaud
AU - Arnold, Dirk
AU - Avouac, Bernard
AU - Awada, Ahmad
AU - de la Cruz-Merino, Luis
AU - Helland, Åslaug
AU - Lassen, Ulrik
AU - Laurent-Puig, Pierre
AU - Normanno, Nicola
AU - Rohrberg, Kristoffer
AU - Taieb, Julien
AU - Stenzinger, Albrecht
N1 - Publisher Copyright:
© 2025 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025/1/1
Y1 - 2025/1/1
N2 - The advent of advanced biomolecular technologies for detecting molecular and genomic signatures of individual tumors has transformed oncology care, introducing proven methodologies that can inform treatment with matched targeted therapies and predict response at the individual patient level. However, access to these technologies has been hampered by multiple barriers, most notably price and obtainability. Other barriers include lack of knowledge of available technologies, concerns about value, and outdated infrastructures that impede critical operations within the clinic or laboratory. Accessibility barriers to advanced biomolecular testing are critically important to patient care, as new technological advances in molecular medicine continue to outpace the implementation of solutions. Given the proven evidence for improved patient outcomes with precision oncology medicines, it is imperative to understand the value afforded by these technologies. The purpose of this narrative review is to describe existing and emerging barriers to access and present a “roadmap to access” that will facilitate the urgently needed discussions to identify solutions for improving access. Implementation of these solutions will raise awareness of available technologies and treatments and their prognostic significance, improve evidence collection for demonstration of value, and fortify clinical and laboratory infrastructure and operations.
AB - The advent of advanced biomolecular technologies for detecting molecular and genomic signatures of individual tumors has transformed oncology care, introducing proven methodologies that can inform treatment with matched targeted therapies and predict response at the individual patient level. However, access to these technologies has been hampered by multiple barriers, most notably price and obtainability. Other barriers include lack of knowledge of available technologies, concerns about value, and outdated infrastructures that impede critical operations within the clinic or laboratory. Accessibility barriers to advanced biomolecular testing are critically important to patient care, as new technological advances in molecular medicine continue to outpace the implementation of solutions. Given the proven evidence for improved patient outcomes with precision oncology medicines, it is imperative to understand the value afforded by these technologies. The purpose of this narrative review is to describe existing and emerging barriers to access and present a “roadmap to access” that will facilitate the urgently needed discussions to identify solutions for improving access. Implementation of these solutions will raise awareness of available technologies and treatments and their prognostic significance, improve evidence collection for demonstration of value, and fortify clinical and laboratory infrastructure and operations.
KW - access
KW - barriers
KW - biomarkers
KW - biomolecular technology
KW - diagnostics
KW - Precision oncology
KW - prognostic
KW - value
UR - http://www.scopus.com/inward/record.url?scp=105007672882&partnerID=8YFLogxK
U2 - 10.1080/14796694.2025.2501523
DO - 10.1080/14796694.2025.2501523
M3 - Article
C2 - 40340714
AN - SCOPUS:105007672882
SN - 1479-6694
VL - 21
SP - 1745
EP - 1752
JO - Future Oncology
JF - Future Oncology
IS - 14
ER -